As we enter 2026, the global clinical landscape is being redefined by deep-learning architectures that identify pathogenic variants with 99% accuracy. In North America and the European Union, the adoption of Artificial Intelligence In Genomics Market protocols has become a mandatory component of pediatric rare disease diagnostics. This shift is particularly evident in medical hubs...